by In2Pharma | Dec 12, 2018 | News
EU Versions 11 & 12 of the Q&A on Safety features for medicinal products for human use have been published in October and November of 2018. Following these updates, multiple questions have been revised (1.20; 1.23; 2.21; 7.15; 8.4; 8.7) and some new questions...
by In2Pharma | Dec 5, 2018 | News
The Netherlands As a result of the Falsified Medicines Directive, companies are obliged to adapt the packaging of their medicines which leads to additional costs. These additional costs cannot always be compensated by a price increase, due to the Drug Price Act (Wet...
by In2Pharma | Oct 15, 2018 | News
The Netherlands An ‘Advisory Group on the Status Determination of Medicinal Products has been established in the Netherlands. This Advisory Group is composed of expert representatives from IGJ, NVWA, MEB and CCMO. The ‘Advisory Group’ advises on...
by In2Pharma | May 24, 2018 | News
Belgium The CMDh has updated the Blue Box requirements on 2 March 2018. Henceforth, mentioning the reimbursement category on the labeling of medicinal products is no longer required in Belgium. Marketing authorization holders are required to remove the reimbursement...
by In2Pharma | Jan 24, 2018 | News
FAMHP The Federal Agency for Medicines and Health Products (FAMHP) calls on Marketing Authorization Holders (MAHs) to verify the delivery status of their medicinal products. Prescription medicinal products are classified into following categories: medicinal products...
